Ambys launches with $140M from series A, Takeda deal

Liver disease company Ambys Medicines (Redwood City, Calif.) launched on Wednesday with $140 million in funding from a series A round and an option partnership with Takeda Pharmaceutical Co. Ltd. (Tokyo:4502).

Ambys' $60 million series A round comprises $40 million from Third Rock Ventures and the remainder from Takeda. ...